High-dose rate brachytherapy in prostate cancer patients--a study on nausea and vomiting.

High-dose rate brachytherapy (HDRB) is one of many treatments for prostate cancer. Despite a reported 80% to 90% success rate in terms of cure rates, nausea and vomiting have been noted as a significant problem. At St. Vincent's Private Hospital, an incidence of nausea and vomiting was estimated at 67% of patients undergoing HDRB. This study examines the possible causes and risk factors of post-operative nausea and vomiting with this treatment option.